RxDoctor Payments Data

Amish Parikh, MD

Cardiovascular Disease · Maitland, FLNPI 1902820830

Payments from drug & device makers

$159,228in general payments, 2019–2025

Across 447 payments — averaging $356.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$101K
  • Lilly USA, LLC$25K
  • Biotronik Inc.$23K
  • Cvrx, Inc.$5K
  • Novartis$853
  • Merck$615
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$3,7502%
  • Speaking & faculty fees$109,57871%
  • Grants$20,00013%
  • Travel & lodging$9,2776%
  • Food & beverage$11,6998%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$159,228 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,906,898
Medicare patients
1,217
Services billed
21,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$393,835
EntrestoSacubitril/Valsartan91$103,716
XareltoRivaroxaban71$69,410
JardianceEmpagliflozin49$40,780
MultaqDronedarone Hcl17$14,111
BrilintaTicagrelor11$9,162
Ranolazine ErRanolazine61$8,030
Metoprolol Succinate413$5,653
Dabigatran EtexilateDabigatran Etexilate Mesylate16$3,445
Prasugrel Hcl11$3,246
Propafenone Hcl52$2,624
Carvedilol253$2,226
Midodrine Hcl49$2,083
Nitroglycerin60$1,797
Losartan Potassium222$1,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$362$393,835376 claims
NovartisEntresto$853$103,71691 claims
Johnson & JohnsonXarelto$302$69,41071 claims
Boehringer IngelheimJardiance$100,766$40,78049 claims
Sanofi-aventis U.S. LLCMultaq$92$14,11117 claims
AstraZenecaBrilinta$46$9,16211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →